학술논문
Artificial Bone Graft Substitutes for Curettage of Benign and Low-Grade Malignant Bone Tumors: Clinical and Radiological Experience with Cerasorb.
Document Type
Academic Journal
Author
Wittig US; Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, Graz, Austria.; Department of Trauma Surgery, Wiener Neustadt State Hospital, Wiener Neustadt, Austria.; Friesenbichler J; Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, Graz, Austria.; Liegl-Atzwanger B; Diagnostic and Research Center for Molecular Biomedicine, Diagnostic and Research Center for Pathology, Medical University of Graz, Graz, Austria.; Igrec J; Division of General Radiology, Department of Radiology, Medical University of Graz, Graz, Austria.; Andreou D; Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, Graz, Austria.; Leithner A; Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, Graz, Austria.; Scheipl S; Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, Graz, Austria.
Source
Publisher: Springer Nature Country of Publication: Switzerland NLM ID: 0137736 Publication Model: eCollection Cited Medium: Print ISSN: 0019-5413 (Print) Linking ISSN: 00195413 NLM ISO Abbreviation: Indian J Orthop Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
0019-5413
Abstract
Background: Artificial bone graft substitutes (ABGS) for curettage of bone tumors are becoming increasingly popular. The aim of this retrospective analysis was to determine the efficacy of the ABGS Cerasorb (Curasan-AG, Kleinostheim, Germany), a beta-tricalcium phosphate (beta-TCP), concerning resorption profile, bone healing, and remodeling after surgery and to evaluate potential complications.
Methods: Forty-three patients suffering from benign and low-grade malignant bone tumors were treated with curettage and refilling of the bony cavity using the ABGS Cerasorb between 2018 and 2021 and included in the final analysis. Clinical follow-up exams with X-rays in two planes were performed 6 weeks, 3 months, 6 months, and 1 year after surgery.
Results: After a mean follow-up period of 14.6 months, radiological consolidation following curettage was observed in all patients. Total resorption was observed in 16.3% of patients; in the other 83.7%, resorption was partial. In four patients, of whom two had a tumor in the distal femur and two in the humeral diaphysis, fractures occurred within 6 weeks after primary surgery.
Conclusion: In conclusion, the beta-TCP Cerasorb seems to be a reliable bone graft substitute with low complication rates and is a suitable alternative to autologous bone grafts or allografts. Nonetheless, it shows a tendency of delayed resorption.
Level of Evidence: III; retrospective cohort study.
Competing Interests: Conflict of interestThe authors have no relevant financial or non-financial interests to disclose.
(© The Author(s) 2023.)
Methods: Forty-three patients suffering from benign and low-grade malignant bone tumors were treated with curettage and refilling of the bony cavity using the ABGS Cerasorb between 2018 and 2021 and included in the final analysis. Clinical follow-up exams with X-rays in two planes were performed 6 weeks, 3 months, 6 months, and 1 year after surgery.
Results: After a mean follow-up period of 14.6 months, radiological consolidation following curettage was observed in all patients. Total resorption was observed in 16.3% of patients; in the other 83.7%, resorption was partial. In four patients, of whom two had a tumor in the distal femur and two in the humeral diaphysis, fractures occurred within 6 weeks after primary surgery.
Conclusion: In conclusion, the beta-TCP Cerasorb seems to be a reliable bone graft substitute with low complication rates and is a suitable alternative to autologous bone grafts or allografts. Nonetheless, it shows a tendency of delayed resorption.
Level of Evidence: III; retrospective cohort study.
Competing Interests: Conflict of interestThe authors have no relevant financial or non-financial interests to disclose.
(© The Author(s) 2023.)